Celgene Announces Phase 3 QUAZAR AML-001 Study of CC-486 as Maintenance Therapy in Patients With Newly Diagnosed Acute Myeloid Leukemia Met Primary and Key Secondary Endpoints

Posted in Biotech by Medtech[y] Staff

September 13, 2019 • 2 min read

Celgene Corporation (NASDAQ: CELG) today announced top-line results from the international phase 3, randomized, double-blind, placebo-controlled study, QUAZAR AML-001. The study evaluated the efficacy and safety of investigational therapy CC-486 as maintenance therapy in patients with newly diagnosed acute myeloid leukemia (AML) ...

Apple announces three groundbreaking health studies

Posted in Future of Healthcare by Medtech[y] Staff

September 12, 2019 • 2 min read

Apple today announced three unprecedented medical studies, in partnership with leading academic and research institutions, that will reach more participants than has ever been possible. The studies will be available on the new Research app,1 which democratizes how medical research is conducted by bringing together academic medical institutions...

AVEO Oncology Announces Updated Overall Survival Hazard Ratio of 0.99 in Phase 3 TIVO-3 Trial of Tivozanib in Renal Cell Carcinoma

Posted in Biotech by Medtech[y] Staff

September 10, 2019 • 2 min read

AVEO Oncology (NASDAQ: AVEO) today announced results from the second prespecified analysis of overall survival (OS) in the TIVO-3 trial. TIVO-3 is the Company’s Phase 3 randomized, controlled, multi-center, open-label study to compare tivozanib (FOTIVDA) to sorafenib in 350 subjects with highly refractory metastatic renal cell carcinoma (RCC)....